Marc Ferrer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12093270/publications.pdf

Version: 2024-02-01

129 papers	8,100 citations	53789 45 h-index	54911 84 g-index

130 all docs	130 docs citations	130 times ranked	14744 citing authors

#	Article	IF	Citations
1	A multiparametric calcium signal screening platform using iPSC-derived cortical neural spheroids.. SLAS Discovery, 2022, 27, 209-218.	2.7	8
2	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	6.4	4
3	Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly. Journal of Medicinal Chemistry, 2021, 64, 9431-9443.	6.4	2
4	Identification of Small Molecule Inhibitors of a Mir155 Transcriptional Reporter in Th17 Cells. Scientific Reports, 2021, 11, 11498.	3.3	2
5	Operationalizing the Use of Biofabricated Tissue Models as Preclinical Screening Platforms for Drug Discovery and Development. SLAS Discovery, 2021, 26, 1164-1176.	2.7	8
6	Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Molecular Cancer Therapeutics, 2020, 19, 52-62.	4.1	24
7	A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells. SLAS Discovery, 2020, 25, 265-276.	2.7	16
8	Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer. Cancers, 2020, 12, 3784.	3.7	3
9	Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model. Cancers, 2020, 12, 1645.	3.7	25
10	Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models. Science Advances, 2020, 6, eaaz2736.	10.3	31
11	Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. Cancer Research, 2020, 80, 2689-2702.	0.9	24
12	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D₃ Dopamine Receptor Agonist. Journal of Medicinal Chemistry, 2020, 63, 5526-5567.	6.4	15
13	Translational in vitro research: integrating 3D drug discovery and development processes into the drug development pipeline. Drug Discovery Today, 2019, 24, 26-30.	6.4	26
14	Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB Journal, 2019, 33, 12435-12446.	0.5	18
15	Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. Frontiers in Oncology, 2019, 9, 994.	2.8	22
16	High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100181.	4.5	18
17	Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy. SLAS Technology, 2019, 24, 28-40.	1.9	14
18	High-Throughput Screening for Drug Combinations. Methods in Molecular Biology, 2019, 1939, 11-35.	0.9	10

#	Article	IF	Citations
19	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell, 2019, 177, 231-242.	28.9	152
20	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1113-1119.	2.2	14
21	A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis. Autophagy, 2019, 15, 1694-1718.	9.1	76
22	Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cellâ€“Like Phenotype. Molecular Cancer Therapeutics, 2019, 18, 2097-2110.	4.1	16
23	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Science Translational Medicine, 2019, 11, .	12.4	129
24	Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. Cell Chemical Biology, 2019, 26, 244-254.e4.	5.2	25
25	Agonist-specific voltage-dependent gating of lysosomal two-pore Na+ channels. ELife, 2019, 8, .	6.0	32
26	Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. Oncogene, 2018, 37, 2630-2644.	5.9	37
27	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 1067-1080.	2.3	9
28	High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Scientific Reports, 2018, 8, 8161.	3.3	199
29	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. European Journal of Medicinal Chemistry, 2018, 156, 79-92.	5.5	9
30	MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Science Translational Medicine, 2018, 10, .	12.4	104
31	Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. Breast Cancer Research and Treatment, 2018, 172, 69-82.	2.5	55
32	A high-throughput imaging and nuclear segmentation analysis protocol for cleared 3D culture models. Scientific Reports, 2018, 8, 11135.	3.3	80
33	Identification of Positive Allosteric Modulators of the D₁ Dopamine Receptor That Act at Diverse Binding Sites. Molecular Pharmacology, 2018, 94, 1197-1209.	2.3	35
34	Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Scientific Data, 2018, 5, 180106.	5.3	20
35	Gastric Acid Secretion from Parietal Cells Is Mediated by a Ca2+ Efflux Channel in the Tubulovesicle. Developmental Cell, 2017, 41, 262-273.e6.	7.0	42
36	PAX3â€“FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discovery, 2017, 7, 884-899.	9.4	221

#	Article	IF	Citations
37	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	6.4	12
38	A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discovery, 2017, 22, 494-506.	2.7	26
39	Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells. Cancer Letters, 2017, 408, 73-81.	7.2	158
40	Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. Scientific Reports, 2017, 7, 11673.	3.3	5
41	Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clinical Cancer Research, 2017, 23, 7301-7311.	7.0	44
42	Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. Journal of Translational Medicine, 2017, 15, 92.	4.4	14
43	Inhibition of PIP4KÎ³ ameliorates the pathological effects of mutant huntingtin protein. ELife, 2017, 6, .	6.0	49
44	Large-scale pharmacological profiling of 3D tumor models of cancer cells. Cell Death and Disease, 2016, 7, e2492-e2492.	6.3	26
45	Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens. Journal of Biomolecular Screening, 2016, 21, 942-955.	2.6	4
46	USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2945-54.	7.1	84
47	Cancer network activity associated with therapeutic response and synergism. Genome Medicine, 2016, 8, 88.	8.2	7
48	Cellâ€based highâ€throughput screening identifies galactocerebrosidase enhancers as potential smallâ€molecule therapies for <scp>K</scp>rabbe's disease. Journal of Neuroscience Research, 2016, 94, 1231-1245.	2.9	2
49	Disease models for the development of therapies for lysosomal storage diseases. Annals of the New York Academy of Sciences, 2016, 1371, 15-29.	3.8	34
50	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Cell, 2016, 30, 764-778.	16.8	116
51	MCOLN1 is a ROS sensor in lysosomes that regulates autophagy. Nature Communications, 2016, 7, 12109.	12.8	369
52	mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening. Scientific Reports, 2016, 6, 37741.	3.3	8
53	Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer. Clinical Cancer Research, 2016, 22, 6204-6216.	7.0	49
54	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkinâ€™s lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1624-1629.	7.1	38

#	Article	IF	Citations
55	Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry, 2016, 55, 1772-1783.	2.5	22
56	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2016, 59, 841-853.	6.4	30
57	Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins. PLoS ONE, 2016, 11, e0161415.	2.5	8
58	High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Scientific Reports, 2015, 5, 13891.	3.3	92
59	Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. Journal of Extracellular Vesicles, 2015, 4, 26533.	12.2	51
60	Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Frontiers in Endocrinology, 2015, 6, 128.	3.5	19
61	Pathway-Based Analysis of Genome-Wide siRNA Screens Reveals the Regulatory Landscape of App Processing. PLoS ONE, 2015, 10, e0115369.	2.5	19
62	Small Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression. Journal of Biomolecular Screening, 2015, 20, 663-672.	2.6	29
63	Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nature Communications, 2015, 6, 6220.	12.8	168
64	Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1). Journal of Medicinal Chemistry, 2015, 58, 5967-5978.	6.4	52
65	Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1373-81.	7.1	170
66	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Science Translational Medicine, 2015, 7, 282ra49.	12.4	118
67	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2â€“dependent adult T-cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12480-12485.	7.1	81
68	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Research, 2015, 124, 20-29.	4.1	9
69	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
70	Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget, 2015, 6, 35247-35262.	1.8	52
71	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cellâ€“like diffuse large B-cell lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2349-2354.	7.1	355
72	The intracellular Ca2+ channel MCOLN1 is required for sarcolemma repair to prevent muscular dystrophy. Nature Medicine, 2014, 20, 1187-1192.	30.7	101

#	Article	IF	Citations
73	Blockade of oncogenic IÎºB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11365-11370.	7.1	166
74	Discovery and Characterization of a G Proteinâ€"Biased Agonist That Inhibits Î²-Arrestin Recruitment to the D2 Dopamine Receptor. Molecular Pharmacology, 2014, 86, 96-105.	2.3	74
75	Allosteric Inhibitors of the Eya2 Phosphatase Are Selective and Inhibit Eya2-mediated Cell Migration. Journal of Biological Chemistry, 2014, 289, 16349-16361.	3.4	46
76	Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nature Communications, 2013, 4, 1953.	12.8	54
77	A TRP Channel in the Lysosome Regulates Large Particle Phagocytosis via Focal Exocytosis. Developmental Cell, 2013, 26, 511-524.	7.0	244
78	A high-throughput screening assay using Krabbe disease patient cells. Analytical Biochemistry, 2013, 434, 15-25.	2.4	26
79	Identification of Small-Molecule Agonists of Human Relaxin Family Receptor 1 (RXFP1) by Using a Homogenous Cell-Based cAMP Assay. Journal of Biomolecular Screening, 2013, 18, 670-677.	2.6	27
80	Identification of a Selective Small-Molecule Inhibitor Series Targeting the Eyes Absent 2 (Eya2) Phosphatase Activity. Journal of Biomolecular Screening, 2013, 18, 85-96.	2.6	33
81	Multiplexing Highâ€Content Flow (HCF) and Quantitative Highâ€Throughput Screening (qHTS) to Identify Compounds Capable of Decreasing Cell Viability, Activating Caspase 3/7, Expressing Annexin V, and Changing Mitochondrial Membrane Integrity. Current Protocols in Chemical Biology, 2013, 5, 195-212.	1.7	6
82	FAM129B is a novel regulator of Wnt/Î²-catenin signal transduction in melanoma cells. F1000Research, 2013, 2, 134.	1.6	12
83	FAM129B is a novel regulator of Wnt/Î²-catenin signal transduction in melanoma cells. F1000Research, 2013, 2, 134.	1.6	21
84	Targeting Cancer Stem Cell Efficient DNA Repair Pathways: Screening for New Therapeutics. , 2013, , 157-172.		0
85	Common Seed Analysis to Identify Off-Target Effects in siRNA Screens. Journal of Biomolecular Screening, 2012, 17, 370-378.	2.6	59
86	A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells. Journal of Biomolecular Screening, 2012, 17, 1231-1242.	2.6	35
87	siRNA off-target effects in genome-wide screens identify signaling pathway members. Scientific Reports, 2012, 2, 428.	3.3	59
88	A Multiplexed siRNA Screening Strategy to Identify Genes in the PARP Pathway. Journal of Biomolecular Screening, 2012, 17, 1316-1328.	2.6	5
89	High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them. Methods, 2012, 57, 234-248.	3.8	11
90	Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 21, 723-737.	16.8	460

#	Article	IF	Citations
91	Parsimonious Discovery of Synergistic Drug Combinations. ACS Chemical Biology, 2011, 6, 1391-1398.	3.4	24
92	Novel Patient Cell-Based HTS Assay for Identification of Small Molecules for a Lysosomal Storage Disease. PLoS ONE, 2011, 6, e29504.	2.5	11
93	cSSMD: assessing collective activity for addressing off-target effects in genome-scale RNA interference screens. Bioinformatics, 2011, 27, 2775-2781.	4.1	14
94	The Use of SSMD-Based False Discovery and False Nondiscovery Rates in Genome-Scale RNAi Screens. Journal of Biomolecular Screening, 2010, 15, 1123-1131.	2.6	25
95	Inhibition of Calcineurin-mediated Endocytosis and Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid Î² Oligomer-induced Synaptic Disruption. Journal of Biological Chemistry, 2010, 285, 7619-7632.	3.4	158
96	A 1,536-Well Ultra-High-Throughput siRNA Screen to Identify Regulators of the Wnt/Î²-Catenin Pathway. Assay and Drug Development Technologies, 2010, 8, 286-294.	1.2	13
97	Identification of Small-Molecule Modulators of Mouse SVZ Progenitor Cell Proliferation and Differentiation Through High-Throughput Screening. Journal of Biomolecular Screening, 2009, 14, 319-329.	2.6	24
98	Error Rates and Powers in Genome-Scale RNAi Screens. Journal of Biomolecular Screening, 2009, 14, 230-238.	2.6	13
99	Knowledge based identification of essential signaling from genome-scale siRNA experiments. BMC Systems Biology, 2009, 3, 80.	3.0	12
100	A Lentivirus-Mediated Genetic Screen Identifies Dihydrofolate Reductase (DHFR) as a Modulator of Î²-Catenin/GSK3 Signaling. PLoS ONE, 2009, 4, e6892.	2.5	18
101	Genome-Scale RNAi Screen for Host Factors Required for HIV Replication. Cell Host and Microbe, 2008, 4, 495-504.	11.0	689
102	Median Absolute Deviation to Improve Hit Selection for Genome-Scale RNAi Screens. Journal of Biomolecular Screening, 2008, 13, 149-158.	2.6	163
103	New Regulators of Wnt/Î²-Catenin Signaling Revealed by Integrative Molecular Screening. Science Signaling, 2008, 1, ra12.	3.6	135
104	A 1,536-Well [³⁵S]GTPÎ³S Scintillation Proximity Binding Assay for Ultra-High-Throughput Screening of an Orphan GÎ±i-Coupled GPCR. Assay and Drug Development Technologies, 2008, 6, 327-337.	1.2	19
105	Hit selection with false discovery rate control in genome-scale RNAi screens. Nucleic Acids Research, 2008, 36, 4667-4679.	14.5	32
106	An Efficient and Fully Automated High-Throughput Transfection Method for Genome-Scale siRNA Screens. Journal of Biomolecular Screening, 2008, 13, 142-148.	2.6	15
107	Integrating Experimental and Analytic Approaches to Improve Data Quality in Genome-wide RNAi Screens. Journal of Biomolecular Screening, 2008, 13, 378-389.	2.6	35
108	High-Throughput Screening by RNA Interference: Control of Two Distinct Types of Variance. Cell Cycle, 2007, 6, 898-901.	2.6	26

#	Article	IF	Citations
109	Miniaturization and Automation of an Ubiquitin Ligase Cascade Enzyme-Linked Immunosorbent Assay in 1,536-Well Format. Assay and Drug Development Technologies, 2007, 5, 493-500.	1.2	8
110	The Use of Strictly Standardized Mean Difference for Hit Selection in Primary RNA Interference High-Throughput Screening Experiments. Journal of Biomolecular Screening, 2007, 12, 497-509.	2.6	90
111	Robust statistical methods for hit selection in RNA interference high-throughput screening experiments. Pharmacogenomics, 2006, 7, 299-309.	1.3	90
112	A miniaturized cell-based fluorescence resonance energy transfer assay for insulin-receptor activation. Analytical Biochemistry, 2006, 355, 267-277.	2.4	12
113	LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17967-17972.	7.1	94
114	Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions. Molecular and Cellular Biology, 2006, 26, 9377-9386.	2.3	176
115	Miniaturization of absorbance assays using the fluorescent properties of white microplates. Analytical Biochemistry, 2005, 342, 254-259.	2.4	34
116	Directed evolution of PDZ variants to generate high-affinity detection reagents. Protein Engineering, Design and Selection, 2005, 18, 165-173.	2.1	23
117	Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochimica Et Biophysica Acta - Biomembranes, 2005, 1712, 161-172.	2.6	211
118	A 1,536-Well cAMP Assay for Gs- and Gi-Coupled Receptors Using Enzyme Fragmentation Complementation. Assay and Drug Development Technologies, 2004, 2, 39-49.	1.2	30
119	A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists. Journal of Medicinal Chemistry, 2004, 47, 6662-6665.	6.4	82
120	A cell-based Î²-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. Analytical Biochemistry, 2004, 334, 344-355.	2.4	58
121	Specific Redistribution of Cell-Penetrating Peptides from Endosomes to the Cytoplasm and Nucleus upon Laser Illumination. Journal of the American Chemical Society, 2004, 126, 15376-15377.	13.7	65
122	Miniaturizable homogenous time-resolved fluorescence assay for carboxypeptidase B activity. Analytical Biochemistry, 2003, 317, 94-98.	2.4	20
123	A PDZ domain-based assay for measuring HIV protease activity: Assay design considerations. Protein Science, 2003, 12, 458-467.	7.6	7
124	A Fully Automated [35S]GTPÎ³S Scintillation Proximity Assay for the High-Throughput Screening of Gi-Linked G Protein-Coupled Receptors. Assay and Drug Development Technologies, 2003, 1, 261-273.	1.2	36
125	A Î²-Lactamase-Dependent Gal4-Estrogen Receptor Î² Transactivation Assay for the Ultra-High Throughput Screening of Estrogen Receptor Î² Agonists in a 3,456-Well Format. Assay and Drug Development Technologies, 2003, 1, 789-800.	1.2	25
126	A PDZ Domain-Based Detection System for Enzymatic Assays. Analytical Biochemistry, 2002, 301, 207-216.	2.4	12

#	Article	IF	Citations
127	Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nature Structural Biology, 1999, 6, 953-960.	9.7	140
128	Peptide Ligands to Human Immunodeficiency Virus Type 1 gp120 Identified from Phage Display Libraries. Journal of Virology, 1999, 73, 5795-5802.	3.4	78
129	Construction and characterization of a radio-iodinatable mutant of recombinant human CD4. Journal of Immunological Methods, 1997, 210, 215-225.	1.4	9